We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.63B
AUM Growth
+$871M
(+18%)
Cap. Flow
-$403M
Cap. Flow
% of AUM
-7.15%
Top 10 Holdings %
Top 10 Hldgs %
32.98%
Holding
166
New
29
Increased
30
Reduced
12
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
+$235M |
| 2 |
AdaptHealth
AHCO
|
+$145M |
| 3 |
CMAX
CareMax, Inc. Class A Common Stock
CMAX
|
+$132M |
| 4 |
Organogenesis Holdings
ORGO
|
+$78.8M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$50.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$110M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$88.6M |
| 3 |
Biogen
BIIB
|
+$86.7M |
| 4 |
Centene
CNC
|
+$67.9M |
| 5 |
The Oncology Institute
TOI
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.23% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cullinan Oncology
CGEM
$1.05B
| $26.9M | 0.48% |
+1,044,000
| New | +$32.1M |
|
52
Xeris Biopharma Holdings
XERS
$1.44B
| $26.7M | 0.47% |
6,553,398
| – | – |
|
53
Fate Therapeutics
FATE
$281M
| $26.4M | 0.47% |
304,000
| – | – |
|
54
Brookdale Senior Living
BKD
$3.62B
| $26.1M | 0.46% |
3,298,000
-4,192,845
| -56% | -$30.1M |
|
|
BPMC
55
DELISTED
Blueprint Medicines
BPMC
| $24.8M | 0.44% |
281,754
+72,754
| +35% | +$6.67M |
|
56
Aveanna Healthcare
AVAH
$2.06B
| $24.7M | 0.44% |
+2,000,000
| New | +$23.7M |
|
57
Cytokinetics
CYTK
$11B
| $24.5M | 0.44% |
1,238,083
-1,322,917
| -52% | -$31.1M |
|
|
NEUE
58
DELISTED
NeueHealth
NEUE
| $24M | 0.43% |
+17,500
| New | +$24M |
|
|
KNTE
59
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $23.7M | 0.42% |
1,020,000
+675,000
| +196% | +$17.2M |
|
|
SPRB
60
Spruce Biosciences
SPRB
$119M
| $22.9M | 0.41% |
+27,293
| New | +$29.1M |
|
61
Alector
ALEC
$164M
| $22M | 0.39% |
1,055,192
| – | – |
|
62
Instil Bio
TIL
$48.4M
| $21.6M | 0.38% |
55,787
| – | – |
|
|
MAACU
63
DELISTED
Montes Archimedes Acquisition Corp. Unit
MAACU
| $21.3M | 0.38% |
+2,000,000
| New | +$20.9M |
|
|
PROF
64
Profound Medical
PROF
$264M
| $21.2M | 0.38% |
1,297,797
| – | – |
|
65
Outset Medical
OM
$74.9M
| $20M | 0.36% |
+26,708
| New | +$20.4M |
|
66
Pharvaris
PHVS
$2.39B
| $19.2M | 0.34% |
1,032,757
| – | – |
|
|
DAWN
67
DELISTED
Day One Biopharmaceuticals
DAWN
| $18.6M | 0.33% |
+818,980
| New | +$17.1M |
|
68
Stereotaxis
STXS
$129M
| $17.8M | 0.32% |
+1,843,000
| New | +$14.5M |
|
69
Janux Therapeutics
JANX
$935M
| $17.5M | 0.31% |
+700,000
| New | +$15.6M |
|
70
Quantum-Si Incorporated
QSI
$168M
| $17.2M | 0.3% |
+1,400,000
| New | +$14.7M |
|
71
Dyne Therapeutics
DYN
$4.04B
| $16.6M | 0.29% |
787,000
+101,000
| +15% | +$1.9M |
|
|
JBIO
72
Jade Biosciences
JBIO
$1.22B
| $16.3M | 0.29% |
+20,408
| New | +$16.3M |
|
|
BLUE
73
DELISTED
bluebird bio
BLUE
| $15.4M | 0.27% |
37,079
| – | – |
|
|
CMRX
74
DELISTED
Chimerix, Inc.
CMRX
| $14.5M | 0.26% |
1,816,221
| – | – |
|
75
Immunocore
IMCR
$1.78B
| $14.1M | 0.25% |
360,966
+189,058
| +110% | +$7.3M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2021 Portfolio in Review
As of Q2 2021, Deerfield Management held 166 positions worth $5.63B, up 18% from $4.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Deerfield Management withdrew a net $403M in Q2 2021, closing 23 positions and reducing 12 holdings. Its most notable exit was Boston Scientific, an estimated $110M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Singular Genomics Systems, Inc. Common Stock worth $250M.
- Deerfield Management's largest Q2 2021 buy was Singular Genomics Systems, Inc. Common Stock: 303,734 shares worth $250M.
- Deerfield Management added most to AdaptHealth in Q2 2021, an estimated $145M increase.
- Deerfield Management's biggest Q2 2021 reduction was Centene, cutting an estimated $67.9M.
- Deerfield Management fully exited Boston Scientific in Q2 2021, selling an estimated $110M.
- Deerfield Management's ten largest holdings make up 33% of its $5.63B portfolio in Q2 2021.
- Deerfield Management opened 29 new positions and closed 23 in Q2 2021.
- Deerfield Management's portfolio value rose 18% quarter-over-quarter to $5.63B.
Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.